¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"infectious hepatitis immunization"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® infectious disease ÇÑ±Û °¨¿°º´
¼³¸í   
  ¹ÙÀÌ·¯½º·ÎºÎÅÍ ±â»ýÃæ Å©±â±îÁöÀÇ »ý¹°À» ¿øÀÎÀ¸·Î Çϴ º´. ¿øÀÎÀº Á¢ÃËÀü¿°¼ºÀ̸ç, º´¿ø¿¡¼­ °¨¿°µÇ´Â °æ¿ìµµ ÀÖ´Ù. °¨¿°À» ¿øÀαտ¡ µû¶ó ºÐ·ùÇϸ頹ÙÀÌ·¯½º, ¼¼±Õ, Å¬¶ó¹Ìµð¾Æ, ¸®ÄÏÂ÷, ¹ÌÄÚ¹ÚÅ׸®¿ò, °õÆÎÀÌ, ¿øÃæ, À±Ãæ, ¿ÜºÎ±â»ýÃæ °¨¿°À¸·Î ³ª´­ ¼ö ÀÖ´Ù.
¿µ¹® infectious mononucleosis ÇÑ±Û Àü¿°´ÜÇÙ±¸Áõ
¼³¸í   
  Epstein-Barr ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ¼­ ÀϾ´Â ±Þ¼º °¨¿°º´. ¹ß¿­, ¼è¾à, ÀÎÈÄÅë, °£±â´ÉÀå¾Ö, ¸²ÇÁÀýºñ´ë, °£Áö¶óºñ´ë, ¸»ÃÊÇ÷¾×ÁßÀÇ ºñÁ¤Çü¸²ÇÁ±¸(´Ü±¸¿Í À¯»çÇÑ) ¹× ¾ç¼¼Æ÷¿¡ ´ëÇÑ °í¿ª°¡ÀÇ ÀÀÁý¼Ò¸¦ Æ¯Â¡À¸·Î ÇÑ´Ù. Áúº´ÀÇ °æ°úÁß ¹× È¸º¹±â°£À» ÅëÇØ¼­ ÇöÀúÇÑ ¹«·ÂÁõÀÌ Áö¼ÓµÈ´Ù. °°Àº ÁõÈıºÀÌ ¿ø¹ß¼º °Å´ë¼¼Æ÷¹ÙÀÌ·¯½º°¨¿°¿¡µµ µ¿¹ÝµÈ´Ù. Å°½ºº´À̶ó°íµµ Çϸç, Ä§¿¡ ÀÇÇÑ EB¹ÙÀÌ·¯½º °¨¿°¿¡ ÀÇÇØ ¹ßº´ÇÑ´Ù. 
¿µ¹® hepatitis ÇÑ±Û °£¿°
¼³¸í   
  °£¿¡ »ý±â´Â ¿°ÁõÀ» ÅëÆ²¾î À̸£´Â ¸». ¹ß¿­-Ȳ´Þ-Àü½Å±ÇÅÂ-¼ÒÈ­ Àå¾ÖÀÇ Áõ»óÀ» º¸À̴µ¥, ÁֵȠ¿øÀÎÀº À½½Ä¹°°ú Ç÷¾×À» ÅëÇÑ ¹ÙÀÌ·¯½º °¨¿°À̸砱נ¹Û¿¡ ¾à¹°, ¾ËÄÚ¿Ã, ¾Ë·¹¸£±â µîÀÌ ¿øÀÎÀΠ°Íµµ ÀÖ´Ù. ÀÌ °£¿°Àº ±× Áö¼Ó±â°£¿¡ µû¶ó¼­ ±Þ¼º°£¿°°ú ¸¸¼º°£¿°À¸·Î ³ª´©´Âµ¥, ¸¸¼º°£¿°Àº 6°³¿ù À̻󠰣¿°ÀÌ Áö¼ÓµÇ´Â °æ¿ì¸¦ ¸»ÇÏ°í ±Þ¼º°£¿°Àº 6°³¿ù ÀÌ»ó Áö¼ÓÇÏÁö ¸øÇϴ °æ¿ì¸¦ ¸»ÇÑ´Ù. ±Þ¼º°£¿°Àº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º-½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇϴ ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀÌ´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༱°£¿°(AÇü)°ú Ç÷û°£¿°(BÇü)ÀÇ µÎ Á¾·ù°¡ Àִµ¥, À̵éÀº ¸ðµÎ Àü¿°¼º ÁúȯÀÌÁö¸¸ °¨¿° °æ·Î´Â ´Ù¸£´Ù. °¨¿° °æ·Î·Î À¯Ç༱°£¿°¹ÙÀÌ·¯½º´Â Ç÷¾×-»ùâÀÚ¾×-´ëº¯ Áß¿¡¼­ Áõ¸íµÇ¹Ç·Î Àü¿°µÈ ¹°-À½½ÄÀ» ÅëÇÏ¿© °æ±¸°¨¿°µÇ°Å³ª È¯ÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃË¿¡ ÀÇÇØ¼­ °¨¿°µÈ´Ù. Ç÷û°£¿°Àº ¿À·ÎÁö ºñ°æ±¸Àû °¨¿°À¸·Î È¯ÀÚÀÇ Ç÷û, Ç÷¾×ÀÇ ÁÖ»ç, È¯ÀÚÀÇ Ç÷¾×¿¡ °¨¿°µÈ ÁÖ»ç±â µîÀ¸·Î °¨¿°µÈ´Ù. Àẹ±â´Â À¯Ç༺°£¿°ÀÌ 2~6ÁÖ°£À̰í, Ç÷û °£¿°Àº 6ÁÖ~6°³¿ù °¡·® µÈ´Ù. Ç÷û°£¿°Àº À¯ÇàÀÇ °èÀý-¿¬·É°ú´Â °ü°è°¡ ¾øÀ¸³ª, À¯Ç༺°£¿°Àº ÁַΠ°¡À»¿¡¼­ °Ü¿ï¿¡ °ÉÃÄ ¸¹°í Ã»¼Ò³â¿¡ ¸¹´Ù. Áõ¼¼´Â ¹ßº´Çϱâ 1ÁÖÀÏ ÀüºÎÅÍ ¿Â¸öÀÌ ³ë°ïÇÏ°í ½Ä¿åÀÌ ¶³¾îÁö¸ç µÎÅëÀÌ ÀÖ°í »óº¹ºÎ¿¡ ºÒÄè°¨ÀÌ »ý±â´Âµ¥, À¯Ç༺°£¿°¿¡¼­´Â È²´ÞÀÌ ³ªÅ¸³ª±â Àü¿¡ ¹ß¿­(38¡É ÀüÈÄ)ÀÌ ÀÖÀ» ¶§°¡ ¸¹°í ¼öÀÏ ÈÄ¿¡ ÇØ¿­µÈ´Ù. ¶Ç, °üÀý-Ç㸮°¡ ¾ÆÇà¶§µµ ÀÖ¾î Ã³À½¿¡´Â °¨±â·Î ¿ÀÀÎÇÒ ¶§°¡ ¸¹´Ù. Ç÷û°£¿°Àº ÀÌ·¯ÇÑ Ãʱâ Áõ¼¼°¡ °¡º±°í ¼­¼­È÷ ¹ßº´Çϴ °ÍÀÌ ¸¹´Ù. ÁÖÁõ¼¼´Â À§ÀåÁõ¼¼¿Í È²´ÞÀ̸ç, ½Ä¿åºÎÁø-±¸Åä-±¸¿ªÁú, »óº¹ºÎÀÇ µÐÅë µîÀÌ ÀϾ¸ç, ¹ßº´ ÈÄ 4~5ÀÏ¿¡ È²´ÞÀÌ ³ªÅ¸³­´Ù. È²´ÞÀº 1ÁÖÀÏÀ» ÀüÈÄÇÏ¿© ÃÖ°í¿¡ À̸£¸ç, ±× ÈÄ 1°³¿ù »çÀÌ¿¡ ¾ø¾îÁö¸é¼­ ´Ù¸¥ Áõ¼¼µµ ÁÁ¾ÆÁø´Ù. °æ°ú´Â ±Þ¼º°£¿°Àº ¾à 70%°¡ ´ë°³ 1~3°³¿ù À̳»¿¡ Ä¡À¯µÇÁö¸¸ »¡¸® Ä¡·áµÇÁö ¾Ê´Â °Í Áß 15%°¡ ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϸç, ±× ÀϺδ °£°æÈ­ÁõÀ¸·Î ÀÌÇàÇÑ´Ù. ±Þ¼º°£¿° Áß¿¡´Â ¶§·Î´Â 10ÀÏ À̳»¿¡ »ç¸ÁÇϴ Àü°Ý¼º°£¿°À̶ó°í Çϴ °Íµµ ÀÖ´Ù. º´ÀÇ Àüü °æ°ú ÁߠȲ´ÞÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¹«È²´Þ¼º °£¿°À̶ó°í Çϴ °Íµµ ÀÖ¾î. ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϴ °Í¿¡´Â ÀÌ ¹«È²´Þ¼ºÀÌ ¸¹Àº °æÇâÀÌ ÀÖ´Ù. Ç÷û°£¿°µµ ¸¸¼ºÈ­Çϱ⠽±´Ù.
¿µ¹® acute hepatitis ÇÑ±Û ±Þ¼º°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼­ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, À̴ ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇϴ ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°À̸砳ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀ̠ã¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿­-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³­´Ù. µÚÀ̾î È²´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º­¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª È²´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â È²´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» Çصµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿­ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀ̠Ư¡À̸砱޼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º­¿î °ÍÀ̠Ư¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀΠ°ÍÀÌ º¸ÅëÀÌ´Ù.
¿µ¹® chronic active hepatitis ÇÑ±Û ¸¸¼ºÈ°µ¿°£¿°
¼³¸í   
  BÇü °£¿°À̳ª ºñAÇü£­ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼­ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Æ¯Â¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀǠħÀ±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ È²´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿­ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈ­Áõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infectious hepatitis
    Àü¿°¼º°£¿°
  • active immunization
    ´Éµ¿¸é¿ªÈ­
  • immunization
    1. ¿¹¹æÁ¢Á¾, ¸é¿ªÁ¢Á¾ 2. ¸é¿ªÈ­
  • latent immunization
    ÀáÀç¸é¿ªÈ­
  • oral immunization
    °æ±¸¸é¿ªÈ­
  • prophylactic immunization
    ¿¹¹æ¸é¿ªÁ¢Á¾
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
  • infectious
    °¨¿°-, Àü¿°-
  • infectious abortion
    °¨¿°À¯»ê
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • infectious arteritis
    °¨¿°µ¿¸Æ¿°
  • infectious arthritis
    °¨¿°°üÀý¿°
  • infectious diarrhea
    Àü¿°¼³»ç
  • infectious disease
    °¨¿°º´
  • infectious enterohepatitis
    °¨¿°Ã¢ÀÚ°£¿°, °¨¿°Àå°£¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunization
    ¿¹¹æÁ¢Á¾, ¸é¿ªÁ¢Á¾, ¸é¿ªÈ­
  • prophylactic immunization
    ¿¹¹æÁ¢Á¾
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • infectious disease
    °¨¿°º´
  • simple infectious glossitis
    ´Ü¼øÀü¿°Çô¿°
  • hepatitis
    °£¿°
  • acute hepatitis
    ±Þ¼º°£¿°
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°
  • serum hepatitis
    Ç÷û°£¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • infectious
    °¨¿°-, Àü¿°-
  • infectious mononucleosis
    Àü¿°´ÜÇÙ±¸Áõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infectious hepatitis
    Àü¿°°£¿°, ¿¡ÀÌÇü°£¿°
  • milkborne infectious hepatitis
    ¿ìÀ¯Àü¿°°£¿°
  • active immunization
    ´Éµ¿¸é¿ªÈ­
  • immunization
    ¿¹¹æÁ¢Á¾, ¸é¿ªÈ­
  • latent immunization
    ÀáÀç¸é¿ªÈ­
  • oral immunization
    °æ±¸¸é¿ªÈ­
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
  • prophylactic immunization
    ¿¹¹æÁ¢Á¾
  • acute infectious disease
    ±Þ¼º°¨¿°º´
  • infectious abortion
    °¨¿°À¯»ê
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • infectious arteritis
    °¨¿°µ¿¸Æ¿°
  • infectious arthritis
    °¨¿°°üÀý¿°
  • infectious diarrhea
    Àü¿°¼³»ç
  • infectious disease
    °¨¿°º´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infectious hepatitis
    Àü¿°¼º °£¿°, AÇü°£¿°
  • infectious hepatitis
    Àü¿°¼º °£¿°(îîæøàõÊÜæú).
  • infectious hepatitis virus
    Àü¿°¼º °£¿° ¹ÙÀÌ·¯½º.
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • immunization
    ¸é¿ª(¹ý)
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(ËçËÑËøÌ¡).
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(çãÛÁïÈðú).
  • immunization therapy
    ¸é¿ª¿ä¹ý(Øóæ¹èþÛö).
  • immunization therapy
    ¸é¿ª¿ä¹ý(¸é¿ª¿ä¹ý).
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • immunization, passive
    ¼öµ¿¸é¿ª
  • immunization, prophylactic
    ¿¹¹æ¸é¿ª
  • DNA, infectious(-tive)
    °¨¿°¼º DNA
  • ID50 (50% infectious dose)
    50% °¨¿°·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infectious hepatitis
    Àü¿°¼º °£¿°(îîæøàõÊÜæú).
  • infectious hepatitis
    Àü¿°¼º °£¿°, AÇü°£¿°
  • infectious hepatitis virus
    Àü¿°¼º °£¿° ¹ÙÀÌ·¯½º.
  • milkborne infectious hepatitis
    ¿ìÀ¯Àü¿°¼º°£¿°(ËíËôËøËçËÛ˧Ëç).
  • milkborne infectious hepatitis
    ¿ìÀ¯Àü¿°¼º °£¿°(éÚêáîîæøàõÊÜæú).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • deliberate immunization
    Àΰø¸é¿ª
  • immunization
    ¸é¿ª(¹ý)
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(çãÛÁïÈðú).
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(ËçËÑËøÌ¡).
  • immunization therapy
    ¸é¿ª¿ä¹ý(¸é¿ª¿ä¹ý).
  • immunization therapy
    ¸é¿ª¿ä¹ý(Øóæ¹èþÛö).
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • immunization, passive
    ¼öµ¿¸é¿ª
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Infectious cause (Virus)
    °¨¿°¿øÀÎ
    [¿¾ ¿ë¾î] °¨¿°¼º¿øÀÎ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunization
    Á¢Á¾(ïÈðú)
  • natural immunization
    ÀÚ¿¬Á¢Á¾(í»æÔïÈðú)
  • hepatitis B surface antigen
    BÇü(úþ) °£¿°(ÊÜæú) Ç¥¸é Ç׿ø(øúØüù÷ê«)
  • type A hepatitis
    AÇü(úþ) °£¿°(ÊÜæú)
  • type B hepatitis
    BÇü(úþ) °£¿°(ÊÜæú)
  • viral hepatitis
    ¹ÙÀÌ·¯½º¼º °£¿° (ÊÜæú)
  • infectious nucleic acid
    °¨¿°¼ºÇÙ»ê(Êïæøàõú·ß«)
  • infectious RNA
    °¨¿°¼º(Êïæøàõ) RNA
  • infectious transfer
    °¨¿°¼º ÀÌÀü(Êïæøàõì¹ï®)
  • median infectious dose
    Á¤Áß °¨¿°·®(ïáñéÊïæøÕá)
  • tissue culture infectious dose
    Á¶Á÷¹è¾ç °¨¿°·® (ðÚòÄÛÆå×ÊïæøÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infectious hepatitis virus
    Àü¿°¼º°£¿°¹ÙÀÌ·¯½º
  • infectious
    °¨¿°¼ºÀÇ
  • fulminant hepatitis
    Àü°Ý¼º°£¿°
  • hepatitis
    °£¿°
  • hepatitis B virus
    BÇü °£¿°¹ÙÀÌ·¯½º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AH abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro...
IBV infectious bronchitis vaccine; infectious bronchitis virus
IPV inactivated poliomyelitis vaccine or virus; infectious pustular vaginitis; infectious pustular vulvo...
HIM hepatitis-infectious mononucleosis; hexosephosphate isomerase
ICH idiopathic cortical hyperostosis; infectious canine hepatitis; intracerebral hematoma; intracranial ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CII Childhood Immunization Initiative
EPI Expanded Program of Immunization
NID National Immunization Day
NIS National Immunization Survey
AIM Acute infectious mononucleosis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • infectious hepatitis virus
    Àü¿°¼º °£¿° ¹ÙÀÌ·¯½º
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • immunization
    ¸é¿ª¹ý, ¸é¿ª Á¶Ä¡, ¿¹¹æ Á¢Á¾
    ÇÇ°Ë ´ë»óÀ» ¸é¿ª »óÅ·ΠÇÏ´Â, ¶Ç´Â ¸é¿ªÀ» ȹµæ½ÃŰ´Â ¹æ¹ý.
  • acute infectious disease
    ±Þ¼º Àü¿°º´
    ¹ßº´ ÈÄ ¼öÀÏ- ¼öÁÖÀÏ·Î Ä¡À¯ ¶Ç´Â »ç¸ÁÇÏ´Â Àü¿°º´. ¾ö¹ÐÇÏ°Ô ±Þ¼º°ú ¸¸¼ºÀ» ±¸º°ÇÒ ¼ö ¾ø´Âµ¥, ÀϹÝÀûÀ¸·Î ¿¬±¸, ´ëÃ¥ÀÇ ÆíÀÇ»ó ºÐ·ùµÈ´Ù. ±Þ¼º Àü¿°º´Àº Áßµ¶ÀÏ °æ¿ì »ç¶÷µéÀÇ ÁÖ¸ñÀ» ¹Þ±â ½±°í, ¿¬±¸, ´ëÃ¥µµ ½Ç½ÃÇϱ⠽±´Ù. ÄÝ·¹¶ó, Æä½ºÆ®, µÎâ, Æú¸®¿À µîÀÌ ±×°ÍÀÌ´Ù. ÇÑÆí °æÁõÀÎ °ÍÀº ±×´ÙÁö Áß¿ä½Ã µÇÁö ¾Ê±â ¶§¹®¿¡ ¿¬±¸, ´ëÃ¥µµ ´Ê¾îÁö°í ÀÖ´Â °ÍÀÌ ¸¹´Ù. ÀÎÇ÷翣ÀÚ, È«¿ª, ¼öµÎ µîÀÌ ±× ¿¹ÀÌ´Ù.
  • acute infectious hemorrhagic fever
    ±Þ¼º °¨¿°¼º ÃâÇ÷ ¿­
  • acute infectious paralysis
    ±Þ¼º Àü¿°¼º ¸¶ºñ
  • angular infectious migrating cheilitis
    °¨¿° À̵¿¼º ±¸°¢ ±¸¼ø¿°
  • avian infectious bronchitis virus
    Á¶·ù °¨¿°¼º ±â°üÁö¿° ¹ÙÀÌ·¯½º
  • following chronic infectious disease
    ¸¸¼º °¨¿° ÁúȯÀÇ ÃßÀû
  • infectious
    °¨¿°¼ºÀÇ
    °¨¿°¿¡ ±âÀÎÇÏ´Â. °¨¿°¿¡ ÀÇÇÏ¿© Àü¿°µÇ´Â.
  • infectious agent
    °¨¿° ÀÎÀÚ
    ¹°¸®Àû, È­ÇÐÀû ¶Ç´Â »ý¹°ÇÐÀûÀÎ È¿°ú¸¦ ÀÏÀ¸Å°´Â Èû, ¼ººÐ ¶Ç´Â ¹°Áú.
  • infectious disease
    °¨¿° Áúȯ, °¨¿°¼º Áúȯ, °¨¿°º´, Àü¿°º´
    °¨¿°À» ÀÏÀ¸Å°´Â ¼÷ÁÖ´Â Á¦°¢±â º´¿øÃ¼¿¡ ´ëÇØ¼­ ƯÀ¯ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»°í ¹ÝÀÀÀÇ º´ÀûÀÎ Á¤µµ¿¡ ´ÞÇØ ÀÓ»ó Áõ»óÀÌ ³ªÅ¸³­ ÁúȯÀ» ¸»ÇÑ´Ù. °¨¿°À» ÀÏÀ¸Äѵµ ¹Ýµå½Ã ¹ßº´ÇÑ´Ù°í´Â ÇÒ ¼ö ¾ø°í ±× º´¿øÃ¼ÀÇ Á¾·ù, º´¿øÃ¼ÀÇ °¨¿°·Â¿¡ °üÇÑ ÀÎÀÚ¿Í °¨¿°ÇÑ »ýüÀÇ °¨¼ö¼º, ¸é¿ª, ±× ¹ÛÀÇ ÀúÇ׷¿¡ °üÇÑ ÀÎÀÚ¿ÍÀÇ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ¼­ °áÁ¤µÈ´Ù.
  • infectious enanthema
    °¨¿°¼º Á¡¸·Áø
  • infectious myositis
    °¨¿°¼º ±Ù¿°
  • law of prophylaxis for infectious disease
    Àü¿°º´ ¿¹¹æ¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
infectious hepatitis immunization See Immunization, hepatitis a.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
immunization, infectious hepatitis See Immunization, hepatitis a.
(12 Dec 1998)
hepatitis a immunization When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain healthcare workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
hepatitis b immunization Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Healthcare workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
immunization, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
immunization, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
immunization, serum hepatitis See Immunization, hepatitis b.
(12 Dec 1998)
vaccination, infectious hepatitis See Vaccination, hepatitis a.
(12 Dec 1998)
hepatitis, infectious See Hepatitis A.
(12 Dec 1998)
hepatitis, infectious canine An adenovirus infection causing fever, oedema, vomiting, and diarrhoea in dogs, especially puppies. In foxes it causes acute encephalitis with convulsions, paralysis, coma, and death.
(12 Dec 1998)
infectious canine hepatitis A disease of dogs, caused by canine adenovirus 1, and characterised by fever, depression, loss of appetite, vomiting, bloody diarrhoea, petechial haemorrhages in the gums, pale mucous membranes, and jaundice.
Synonym: hepatitis contagiosa canis, Rubarth's disease.
(05 Mar 2000)
infectious hepatitis <virology> A form of viral hepatitis, known as infectious hepatitis, due to its ability to be spread through personal contact with oral secretions or stool. Virus will be shed in the stools of an infected individual 2-3 weeks prior to the onset of any symptoms. Hepatitis A may also be transmitted sexually. Symptoms are similar to those of influenza, but the skin and eyes may become yellow. Recent travel to a third world country is a risk factor. There is no specific treatment but infected individuals should avoid potentially hepatotoxic substances.
The virus is a small (27nm diameter) single stranded RNA virus with some resemblance to enteroviruses such as polio.
(27 Sep 1997)
infectious hepatitis virus <virology> An RNA virus (hepatovirus) in the family Picornaviridae, that is the causative agent of viral hepatitis type A.
The virus replicates in hepatocytes and is presumed to reach the intestine via the bile duct. Transmission occurs by the faecal-oral route.
Synonym: infectious hepatitis virus.
(20 Sep 2002)
infectious necrotic hepatitis of sheep A disease of sheep caused by the bacterium Clostridium novyi, which invades livers damaged by the fluke Fasciola hepatica and causes severe necrosis and death; this disease occurs in nearly all parts of the world, including the U.S. Sometimes called black disease because of the extensive haemorrhages seen on the inner surface of the pelt when it is removed.
Synonym: black disease.
(05 Mar 2000)
active immunization The production of active immunity.
(05 Mar 2000)
anthrax immunization A series of six shots over six months and booster shots annually, the anthrax vaccine now in use in the USA was first developed in the 1950s and approved by the Food and Drug Administration for general use in 1970. It is produced by the Michigan Biologic Products Institute of Michigan's Department of Health and is given routinely to veterinarians and others working with livestock. In December, 1997 it was announced that all US military would receive the vaccine, as do the military in the UK and Russia, the reason being concern that anthrax might be used in biologic warfare.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hepatitis
    °£¿°
  • hepatitis A
    AÇü °£¿°;Àü¿°¼º(Ç÷û)°£¿°
  • immunization
    ¸é¿ª(¹ý);¸é¿ªÁ¶Ä¡;¸éÁ¦;(¸é¿ª)¿¹¹æÁÖ»ç
  • passive immunization
    ¼öµ¿ ¸é¿ª
  • infectious
    Àü¿°ÇÏ´Â
  • infectious
    Àü¿°¼ºÀÇ;Àü¿°º´ÀÇ;Àü¿°µÇ±â ½¬¿î(catching);¿Å±â(Àü´ÞµÇ±â)½¬¿î
  • infectious hopatitis
    (ÀÇ)Àü¿°¼º(À¯Ç༺)°£¿°
  • infectious mononucleosis
    Àü¿°¼º ´ÜÇÙ¼¼Æ÷Ãþ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á